Delving into the Latest Updates on 11C-PBR-170 with Synapse

Overview

Basic Info

Drug Type

Diagnostic radiopharmaceuticals

Synonyms

PRB-170-[11C], carbon-11-PBR-170

Target

TSPO

Mechanism

TSPO modulators(Translocator protein modulators)

Therapeutic Areas-

Active Indication-

Inactive Indication-

Originator Organization

Australian Nuclear Science & Technology Organisation

Active Organization-

Inactive Organization

Australian Nuclear Science & Technology Organisation

Drug Highest PhasePendingDiscovery

First Approval Date-

Regulation-

The 57th Annual Meeting of the Society of Nuclear Medicine, held in Salt Lake City, UT, USA, included topics covering new developments in imaging agents and radiopharmaceutical therapies in the field of nuclear medicine. This conference report highlights selected presentations related to imaging of the brain, the prediction of heart disease, and the detection and treatment of various cancers. Investigational drugs discussed include TF-2 plus [68Ga]IMP-288 and TF-2 plus [111In]IMP-288 (both Immunomedics Inc), [11C]PBR-170 (Royal Prince Alfred Hospital/Australian Nuclear Science & Technology Organization), [11C]LY-2795050 (Eli Lilly & Co), yttrium (90Y) clivatuzumab tetraxetan (Garden State Cancer Center/Immunomedics Inc), [18F]LMI-1195 (Lantheus Medical Imaging Inc), fluciclovine (18F) (GE Healthcare/Nihon Medi-Physics Co Ltd), [99mTc]MIP-1340 and [99mTc]MIP-1407 (both Molecular Insight Pharmaceuticals Inc).

100 Deals associated with 11C-PBR-170

Login to view more data